Novacyt SA (ALNOV) Habari na Bei kuhusu Hisa

ALNOV:EPA

Novacyt SA

€ 0.44

-1.12%

(-0.0050) Siku 1

30 Okt, 17:35:10 GMT +1 · EUR

Alama zote

	Alama	Bei	Tofauti	Tofauti ya asilimia

Inatayarisha maarifa maarufu ya ALNOV...

Fungua

€ 0.44

Juu

€ 0.44

Chini

€ 0.44

Mtaji wa soko

30.51M

Wastani wa kiasi cha mauzo

elfu 195.23

Kiasi cha mauzo ya hisa

elfu 47.41

Juu kwa wiki 52

€ 1.04

Chini kwa wiki 52

€ 0.29

EPS

-€ 0.37

Hisa za wawekezaji

72.59M

Idadi ya wafanyakazi

228

Fungua

€ 0.44

Juu

€ 0.44

Chini

€ 0.44

Mtaji wa soko

30.51M

Wastani wa kiasi cha mauzo

elfu 195.23

Kiasi cha mauzo ya hisa

elfu 47.41

Juu kwa wiki 52

€ 1.04

Chini kwa wiki 52

€ 0.29

EPS

-€ 0.37

Hisa za wawekezaji

72.59M

Idadi ya wafanyakazi

228

Hisa zinazohusiana

Habari

Kutoka kwenye vyanzo vya wavuti na washirika wa habari

shattered.io

dakika 52 zilizopita

Anthropic’s $80.7B Loss Meets Shaky Partners [2026]

Yahoo Finance

saa 13 zilizopita

Tom Lee Thinks One Investor Might Be Behind Nasdaq’s Stock Crash

CNBC

saa 15 zilizopita

Anthropic's path to the Nasdaq just got a lot bumpier

MarketWatch

siku 1 iliyopita

The selloff in tech stocks is shifting into overdrive

Wasifu

Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare. In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia

Kuhusu Novacyt SA

Afisa Mkuu Mtendaji (CEO)David Allmond

Wafanyakazi228

Lilianzishwa3 Jul 2006

Makao makuu-

Sekta-

Tovutinovacyt.com

Thamani zote katika GBP	Sep 2025	Des 2025	Mac 2026	Jun 2026
Mapato	5.12M	5.12M	5.78M	5.78M
Gharama ya bidhaa zilizouzwa	2.61M	2.61M	2.56M	2.56M
Gharama ya mapato	2.61M	2.61M	2.56M	2.56M
Gharama za utafiti na maendeleo	1.03M	1.03M	1.06M	1.06M
Jumla ya gharama za utafiti na maendeleo	-	-	-	-
Gharama za uuzaji, za jumla na za usimamizi	4.69M	4.69M	4.65M	4.65M
Gharama ya uendeshaji	5.54M	5.54M	5.66M	5.66M
Jumla ya gharama za uendeshaji	8.16M	8.16M	8.22M	8.22M
Mapato ya uendeshaji	-3.04M	-3.04M	-2.44M	-2.44M
Mapato mengine yasiyo ya uendeshaji	elfu -23.00	elfu -23.00	elfu -47.50	elfu -47.50
EBT ikijumuisha vipengee visivyo vya kawaida	-10.16M	-10.16M	-2.91M	-2.91M
EBT bila kujumuisha vipengee visivyo vya kawaida	-2.52M	-2.52M	-2.80M	-2.80M
Gharama ya kodi ya mapato	-1.81M	-1.81M	elfu -49.50	elfu -49.50
Kiwango cha kodi kinachotumika	17.85%	17.85%	1.70%	1.70%
Gharama nyingine za uendeshaji	elfu -180.50	elfu -180.50	elfu -44.00	elfu -44.00
Mapato halisi	-8.27M	-8.27M	-2.90M	-2.90M
Kiwango cha faida halisi	-161.60%	-161.60%	-50.13%	-50.13%
Mapato kwa kila hisa	-	-	-	-
Mapato ya riba na uwekezaji	elfu 149.00	elfu 149.00	elfu 63.00	elfu 63.00
Gharama ya riba	elfu -146.00	elfu -146.00	elfu -139.00	elfu -139.00
Jumla ya gharama halisi za riba	elfu 3.00	elfu 3.00	elfu -76.00	elfu -76.00
Gharama za kushuka kwa thamani na za kulipa deni	-	-	-	-
Mapato ya kampuni kabla ya riba, kodi, kushuka thamani na kulipa madeni	3.46M	3.46M	-1.88M	-1.88M
Faida au hasara kutokana na uuzaji wa vipengee	elfu -3.00	elfu -3.00	elfu 8.00	elfu 8.00

Fedha

Uliza chochote